What Is Bevacizumab?
Bevacizumab is cancer fighting drug that is sometimes classified as a chemotherapy drug. It is an antiangiogenic agent, meaning that it stops blood vessel formation to eliminate tumors’ supply of oxygen and nutrients to slow their growth and spread.
Doctors may inject it or give it through an intravenous drip, a process that can take a few hours. Patients generally need the drug once every three weeks. In a 2021 research study, 61% of mesothelioma patients prescribed a combination of atezolizumab with bevacizumab had no progression of disease after one year, and overall survival at one year was 85%.
In early clinical trials, bevacizumab (Avastin) helped some mesothelioma patients live longer when combined with chemotherapy drugs cisplatin and pemetrexed (Alimta). In a 2016 phase III clinical trial in France, patients taking a combination of the three drugs survived an average of 18.8 months, compared to 16.1 months for patients only receiving cisplatin and pemetrexed.
Bevacizumab has rare but serious side effects. The phase III clinical trial showed that although the side effects were significantly higher for patients taking bevacizumab, they were deemed mostly manageable.
How Does Bevacizumab Work?
Unlike the way chemotherapy attacks rapidly dividing cancer cells, bevacizumab ensures that tumors don’t receive necessities like oxygen and nutrients. It inhibits angiogenesis, which is the growth of blood vessels within the tumor.
If angiogenesis occurs, mesothelioma cells have a support system within the body and can divide and spread more easily. But without angiogenesis, cancer cells are starved of vital nutrients and slowly die.
When bevacizumab prevents angiogenesis, it stops mesothelioma from spreading and kills cancer cells that are already present.
|Dosage||15 mg/kg every three weeks|
|Drug Class||Anti-angiogenic agent|
|Medical Code||J9035, C9257|
|Related Drug||Bevacizumab-awwb (Mvasi)|
|Interacting Drug||Quadramet, deferiphrone, pantiumumab, sunitinib, thalidomide|
|Medical Studies||Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma|
|FDA Warning||Gastrointestinal perforation or fistula, arterial thromboembolic events, hypertension, proteinuria, ovarian failure, infusion reactions, posterior reversible encephalopathy syndrome|
In some cancers, including mesothelioma, it is commonly used in combination with other chemotherapy drugs such as a cisplatin-based chemotherapy regimen. Some clinicians have also combined bevacizumab with a second-line chemotherapeutic agent called gemcitabine.
When used in this combined treatment fashion, bevacizumab works to stop angiogenesis while other drugs have a direct cytotoxic effect on the tumor cells. Oncologist have expressed concern that some treatment combinations with bevacizumab may increase the risk of side effects.
Side Effects of Bevacizumab
Bevacizumab commonly causes minor side effects such as dizziness, dry mouth, fatigue, heartburn and loss of appetite. In rare cases, it may cause severe side effects such as blood clots in the lungs, hemorrhaging, holes in the stomach and low white blood cell count. These potentially deadly complications are most common when it is used in conjunction with a chemotherapy drug.
A study of clinical trial results revealed that patients treated with bevacizumab and chemotherapy are 1.5 times more likely to die because of treatment complications than patients treated with chemotherapy alone.
Results of Bevacizumab Studies
The combination was successful in slowing disease progression in half of patients. Overall, patients lived a median of 5.8 months after being treated with the drug. Researchers reported that it was well-tolerated and warranted further study.
In a case study the following year, a mesothelioma patient underwent treatment with bevacizumab and gemcitabine after other treatments had failed to shrink his tumor or control his symptoms. The combination helped prevent fluid buildup and pain, leading to a better quality of life.
This finding suggests that bevacizumab may aid in palliative, symptom-reducing care in addition to potentially curative, life-extending treatment.